Log In
Print this Print this

onapristone ER

  Manage Alerts
Collapse Summary General Information
Company Invivis Pharmaceuticals Inc.
DescriptionExtended-release formulation of a progestin receptor antagonist
Molecular Target Progestin receptor
Mechanism of ActionProgesterone receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationProstate cancer
Indication DetailsTreat advanced castration-resistant prostate cancer (CRPC)
Regulatory Designation
PartnerArno Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today